Dicerna Pharmaceuticals Announces The Appointment Of Theodore T. Ashburn, M.D., Ph.D. To Senior Vice President, Product Strategy And Operations, And Inducement Grant Of Stock Options Under NASDAQ Listing Rule 5635 (C)(4)

Dicerna Pharmaceuticals, Inc. (“Dicerna” or the “Company”) (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced the appointment of Theodore (Ted) T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations. Dr. Ashburn brings 15 years of product and corporate development experience to Dicerna. In this newly-created position, Dr. Ashburn will lead product strategy and operational efforts for the Company’s Dicer substrate short interfering RNAi (DsiRNA) therapeutics.

Help employers find you! Check out all the jobs and post your resume.